Summary of minutes of EUCAST Steering Committee Meeting  
Munich, Germany, 11-12 September 2006

Attending
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom  
Dr Rafael Canton RC Clinical Data Co-ordinator Spain  
Prof Claude-James Soussy CJ-S SFM France  
Prof Gunnar Kahlmeter GK Chairperson Sweden  
Dr Johan W. Mouton JM CRG The Netherlands  
Prof Inga Odenholt IO SRGA Sweden  
Prof Arne Rodloff AR DIN Germany  
Dr Martin Steinbakk MS NWGA Norway  
Prof Waleria Hryniewicz WH EUCAST Poland  

Apologies
Prof Alasdair P. MacGowan AM BSAC United Kingdom  
Prof Pietro Varaldo PV EUCAST Italy  
Dr Fred Goldstein FG SFM France

EMEA
Prof János Borvendég JB EMEA Co-rapporteur, Hungary  
Prof András Szalka AS EMEA expert, Hungary

1 Chairman’s welcome  
GK welcomed WH as a new representative of the EUCAST General Committee. CJ-S represented SFM in place of FG.

2 Minutes of meeting of 12-13 June 2006  
With minor corrections the minutes were accepted as a correct record.

3 Matters arising from minutes of meeting of 12-13 June 2006  
Review of EUCAST website: The website has been revised. Report errors or problems to DB.

- β-lactam inhibitor combinations: MIC distributions are being collected.
- Quinolone rationale documents: Will be completed soon.
- Formatting of rationale documents: It is not possible to print breakpoint tables automatically when rationale documents are printed.
- Version numbers in breakpoint tables: The list of amendments has the most recent at the top.
- Cefepime and aztreonam footnotes: Modified in breakpoint tables.
- Breakpoint tables for cephalosporins, carbapenems and aztreonam: Cefuroxime exception note provided by DIN and will be provided by NWGA. Discussion of ceftazidime breakpoints for Acinetobacter and inconsistencies for Pseudomonas with ceftazidime and aztreonam was deferred to 2007.
- Collection of data for penicillins: Clinical data and dosages are to be added.
- Further data received from companies on new agents.
- Cephalosporin technical note: Draft has been updated.
- Suggestions to EFSA: Note received thanking the Steering Committee for their suggestions.
- Erythromycin for Shigella spp and E. coli enteric infections: References noted.
- Macrolide MIC distributions for H. influenzae and staphylococci: Distributions required.
Footnote regarding *Legionella* and erythromycin and azithromycin: Added to the draft table.

Quinupristin-dalfopristin MIC data: Distributions required.

Draft macrolide breakpoint table update: The table has been updated and redistributed.

Penicillin breakpoints: Noted lack of evidence of a relationship between MIC and outcome Pk/Pd etc. for anaerobes in human infections.

Penicillin breakpoints: More MIC distributions for viridans streptococci are needed.

New topical agent: Epidemiological breakpoints will be set.

4 **Declarations of interest**
Updated completed forms to be returned.

5 **New antimicrobial agents**
No additional information.

6 **Technical notes**
Tigecycline and linezolid notes will be published in CMI this year.

7 **Rationale documents**
Tigecycline, linezolid and daptomycin documents are on the EUCAST website.

8 **Fluconazole rationale document**
Following minor modifications the document will go for wider consultation.

9 **New quinolone**
There was preliminary discussion of breakpoints.

10 **Penicillin breakpoints**
The draft breakpoints for intravenous and oral penicillins were reviewed. Tables will be updated and revised tables distributed for further comment from national committees.

11 **Status of rationale documents and technical notes**
Action was assigned to individuals for all outstanding documents. The management of preparation of rationale documents and technical notes will be taken over by the Clinical Data Coordinator, RC.

12 **ECCMID 2007, Munich**
A symposium on expert rules will be included.

13 **Expert rules sub-committee**
Ways of speeding up the work of the group will be explored.

14 **Website**
Some further updates to the EUCAST website were agreed.

15 **ISO/CEN**
The reference broth microdilution method was out for final vote. The document on assessment of in vitro devices was out for first vote and comment. The proposal to prepare an antifungal susceptibility testing document will be discussed at the next meeting of CEN TC/140 in June 2007.

16 **Macrolides**
Breakpoints will be reviewed at the meeting on 20-21 November 2006.
|   | **17** EMEA/EUCAST procedural problems  
Problems raised by CA-SFM were discussed. On 16th November 2006 GK and DB will meet with EMEA to review procedures. |
|---|---|
|   | **18** New quinolone meeting with EMEA experts and rapporteurs  
There was preliminary discussion of breakpoints. |
|   | **19** New quinolone meeting with EMEA experts and rapporteurs and the company  
There was preliminary discussion of breakpoints. |
|   | **20** Any other business  
Norfloxacin breakpoints: To be updated when breakpoints revised.  
Consultation from ESCMID study group on antimicrobial resistance development of anaerobic bacteria (ESGARAB): Agents to be included in European surveillance were suggested.  
Tigecycline discrepancy between EUCAST breakpoints and SPC: Correction of breakpoint error is required.  
“Other” agents: Agreed to start looking at breakpoints for miscellaneous agents. |
|   | **21** Next meetings  
3-4 April 2007 Munich (after ECCMID 31 March - 3 April 2007).  
14-15 June 2007, Copenhagen.  
6-7 September 2007. Venue to be agreed.  
19-20 November 2007. Venue to be agreed. |

Ratified summary of minutes of meeting 11-12 September 2006